Luminescent iridium complexes for detection of molybdate

Reactions of [Ir(CŸN)2Cl]2 [HCŸN = 2-(3-R-phenyl)pyridine, 2-(3-R-phenylpyrazole) R = H, Me] with Me2-phencat give luminescent complexes [Ir(CŸN)2(Me2-phencat)][PF6] (Me2-2a, b, c)[PF6]. Deprotection of the methoxy groups with BBr3 is problematic as simultaneous bromination of the cyclometallated phenyl groups occurs. However, deprotection of Me2-phencat with BBr3 followed by complexation with [Ir(CŸN)2Cl]2 gives luminescent complexes [Ir(CŸN)2(H2-phencat)][PF6] (H2-3a, c)[PF6], which are luminescent sensors for molybdate

Ruthenium Anticancer Compounds: Challenges and Expectations

Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imidazole) and [IndH] trans-[RuCl4(Ind)2] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms

In situ NMR characterisation of an intermediate in the catalytic hydrogenation of CO2 and HCO3- in aqueous solution

4nonenoneG. LAURENCZY; S. JEDNER; ALESSIO E.; P. J. DYSONG., Laurenczy; S., Jedner; Alessio, Enzo; P. J., Dyso

Half-sandwich RuIIsingle bond[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity

The preparation, structural characterization, and chemical behavior in aqueous solution of a series of new Ru-[9]aneS(3) half-sandwich complexes of the type [Ru([9]aneS(3))Cl(N-N)][CF3SO3] and [Ru([9]aneS(3))(dmso-S)(N-N)][CF3SO3](2) (5-15, N-N = substituted bpy or 2 x 1-methylimidazole) are described. The X-ray structures of [Ru([9]aneS(3))Cl(3,3'-H(2)dcbpy)][CF3SO3] (9) (3,3'-H(2)dcbpy = 3,3'-dicarboxy-2,2'-bipyridine), [Ru([9]aneS(3))Cl(4,4'-dmobpy)][CF3SO3] (13) (4,4'-dmobpy = 4,4'-dimethoxy-2,2-bipyridine), and [Ru([9]aneS(3))Cl(1-MeIm)(2)][CF3SO3] (15) (1-Melm = 1-methylimidazole) were also determined. The new compounds are structurally similar to anticancer-active organometallic half-sandwich complexes of formula [Ru(eta(6)-arene)Cl(N-N)][PF6]. Three chloro compounds (5, 9, 15) were tested in vitro for cytotoxic activity against two human cancer cell lines in comparison with the previously described [Ru([9]aneS(3))Cl(en)][CF3SO3] (1, en = ethylenediamine), [Ru([9]aneS(3))Cl(bpy)][CF3SO3] (2), and with their common dmso precursor [Ru([9]aneS(3))Cl(dmso-S)(2)][CF3SO3] (3). Only the ethylenediamine complex 1 showed some antiproliferative activity, ca. one order of magnitude lower than the reference organometallic half-sandwich compound RM175 that contains biphenyl instead of [9]aneS(3). This compound was further tested against a panel of human cancer cell lines (including one resistant to cisplatin